Radiotherapy for inoperable lung cancer

Clinical Oncology

Volumn 13, Issue 2, 2001, Pages 86-87

  Timothy, A R ^a   Girling, D J ^b   Saunders, M I ^c   Macbeth, F ^d   Hoskin, P J ^c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

^d VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MATRIX METALLOPROTEINASE INHIBITOR;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLASSIFICATION; CLINICAL STUDY; CONTROLLED STUDY; HUMAN; LUNG FUNCTION; LUNG NON SMALL CELL CANCER; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; SYMPTOMATOLOGY; TREATMENT INDICATION;

EID: 0035030693     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2001.9224     Document Type: Article

References (10)

1. Medical Research Council Lung Cancer Working Party. Inoperable non-small cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Br J Cancer 1991;63;265-70.
2. Medical Research Council Lung Cancer Working Party. A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Br J Cancer 1992;65:934-41.
3. Cox JD, Azarnia N, Byhardt RW, et al. A randomized Phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Theray Oncology Group Stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 8311. J Clin Oncol 1990;8:1543-55.
4. Saunders M, Dische S, Barrett A, et al., on behalf of the CHART Steering Committee. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multi-centre trial. Lancet 1997;350:161-5.
5. Bailey AJ, Parmar MKB, Stephens RJ, on behalf of the CHART Steering Committee. Patient-reported short-term and long-term physical and psychological symptoms: results of the continuous hyperfractionated accelerated radiotherapy (CHART) randomized trial in non-small-cell lung cancer. J Clin Oncol 1998;16:3082-93.
6. Saunders M, Dische S, Barrett A, et al., on behalf of the CHART Steering Committee. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised trial. Radiother Oncol 1999;52:137-48.
7. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997;15:2996-3018.
8. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: a metaanalysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
9. Medical Research Council Lung Cancer Working Party. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small-cell lung cancer and good performance status. Clin Oncol 1996;8:167-75.
10. Girling DJ, Falk SJ, White RJ, et al., on behalf of all collaborators. Immediate versus delayed thoracic radiotherapy (TRT) in patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) and minimal symptoms: results of an MRC/BTS randomised trial. Lung Cancer 2000 In press.